Carfilzomib approved by US FDA as combination regimen with daratumumab and dexamethasone for patients with relapsed/refractory multiple myeloma

Approval was based on Phase 3 RCT which showed addition of daratumumab to dexamethasone plus carfilzomib resulted in 37% reduction in risk of disease progression or death (hazard ratio 0.63; 95% CI: 0.464-0.854; p=0.0014) vs. dexamethasone and carfilzomib.


Biospace Inc.